Clearside Biomedical and Omeros Corp. both have promising products that should win regulatory approval in the coming months.
CNC has been a hard stock to trade and to analyze
My recommendation is not for the shy, timid, or new trader.
Investors can now look to buy shares of this biotech firm.
Traders should approach PKI from the long side at current levels.
This drugmaker is making a historic upside breakout. Let's check the charts.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Here's the area where I would like to go long MRNA.
A Real Money subscriber asks. We answer.
Omega Healthcare offers a 7% yield and promise of growth.